New drug combo aims to tame aggressive lymphoma in frail patients
NCT ID NCT07714421
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This early-phase trial is testing a two-step treatment for elderly or unfit patients with untreated diffuse large B-cell lymphoma (DLBCL). First, patients receive the immunotherapy drug epcoritamab alone, then they receive epcoritamab combined with a reduced-dose chemotherapy cocktail called pola-R-mini-CHP. The goal is to find a safe, tolerable dose that can effectively fight the cancer while being gentler than standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of epcoritamab, polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone
- What this could lead to
- If successful, this approach could offer a safer, effective treatment option for elderly or unfit patients with diffuse large B-cell lymphoma who cannot tolerate standard chemotherapy.
- What could go wrong
- This is an early phase I trial with only 20 participants, so safety and dosing are still being determined. The combination may cause significant side effects or may not improve outcomes compared to existing therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
Contact Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the key to better CAR-T therapy lie in the gut?
- Can a second CAR T-Cell infusion beat lymphoma that returns?
- Liver-Friendly lymphoma treatment? new drug dosing study offers hope
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Double-Pronged immune cells take aim at stubborn blood cancers